- Home
- CR vs PCVX Comparison
CR vs PCVX Comparison
Compare CR & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CR | PCVX |
|---|---|---|
| Founded | 1855 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 6.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CR | PCVX |
|---|---|---|
| Price | $195.38 | $44.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $223.20 | $105.00 |
| AVG Volume (30 Days) | 285.6K | ★ 1.3M |
| Earning Date | 01-26-2026 | 02-24-2026 |
| Dividend Yield | ★ 0.47% | N/A |
| EPS Growth | ★ 37.96 | N/A |
| EPS | ★ 6.25 | N/A |
| Revenue | ★ $2,268,100,000.00 | N/A |
| Revenue This Year | $10.83 | N/A |
| Revenue Next Year | $14.14 | N/A |
| P/E Ratio | $31.42 | ★ N/A |
| Revenue Growth | ★ 19.64 | N/A |
| 52 Week Low | $127.04 | $27.66 |
| 52 Week High | $203.89 | $93.77 |
Technical Indicators
Market Signals| Indicator | CR | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 64.36 | 46.03 |
| Support Level | $183.16 | $43.95 |
| Resistance Level | $188.96 | $47.76 |
| Average True Range (ATR) | 3.87 | 1.69 |
| MACD | 0.63 | -0.10 |
| Stochastic Oscillator | 94.25 | 39.85 |
Price Performance
Historical ComparisonAbout CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and electronics, and process flow technologies. Crane generated approximately $2.1 billion in revenue in 2024.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.